Gemcitabine Hydrochloride CAS 122111-03-9 API Active Pharmaceutical Ingredient

Product Description:

Product Name: Gemcitabine hydrochloride CAS NO: 122111-03-9                    

Synonyms:

dFdC Gemzar (Lilly) LY-188011 dFdC dFdCyd;

2'-Deoxy-2',2'-difluorocytidine;

Chemical & Physical Properties:

Appearance: White crystalline granular, odorless

Assay :≥99.0%

Boiling Point: 482.7℃ at 760 mmHg

Melting Point: >250℃ dec

Flash Point: 245.7℃

Vapor Pressure: 2.41E-11mmHg at 25℃

Storage Temp.: Desiccate at +4℃

Solubility: H2O: ≥10mg/mL

Safety Information:

Safety Statements: S25; S26; S36/37; S53

HS Code: 2934999090

Risk Statement: R21

Hazard Codes: Xi,Xn

WGK Germany: 3

RTECS: HA3840000

Gemcitabine hydrochloride is a synthetic novel difluoro nucleoside drug that is anti-metabolic and antineoplastic. It is researched and developed by the Eli Lilly and Company and approved to be listed in South Africa, Sweden, the Netherlands, Australia and other countries in 1995. The United States Food and Drug Administration ( referred FDA) approved it as the first-line therapy for the clinical treatment of non-small cell lung cancer and pancreatic cancer. The main manufacturers of gemcitabine hydrochloride in domestic are Jiangsu Stock hausen Pharmaceutical Co., Ltd., and Harbin, Yu Heng Pharmaceutical company.

Gemcitabine hydrochloride, as a pro-drug, is a good substrate for the acidification of deoxygenation of thymine kinase phosphorus in the cell, and under the action of the enzyme, it can be converted into the following metabolites: gemcitabine mono-phosphate (dFdCMP), gemcitabine diphosphate (dFdCDP) and gemcitabine triphosphate (dFdCTP), among which the latter two are the active products.

In recent years, new drugs such as gemcitabine, paclitaxel, docetaxel, vinorebine are effective drugs for the treatment of non-small cell lung cancer (abbreviated NSCLC). Compared with traditional chemotherapy drugs, these drugs have the advantages of high curative effect and low toxicity.

Suitable for the treatment of inoperable advanced or metastatic pancreatic cancer and the treatment of locally advanced or metastatic non-small cell lung cancer, and the treatment for mid-term and advanced non-small cell lung cancer, non-small cell lung cancer, pancreatic cancer, bladder cancer, breast cancer and other solid tumors.

If you are interested in our products or have any questions, please feel free to contact us!

Products under patent are offered for R & D purpose only. However, the final responsibility lies exclusively with the buyer.